Items where authors include "Kaplan, R"

Article

Brown, LC, Graham, J, Fisher, D et al. (15 more authors) (2022) Experiences of running a stratified medicine adaptive platform trial: Challenges and lessons learned from 10 years of the FOCUS4 trial in metastatic colorectal cancer. Clinical Trials, 19 (2). pp. 146-157. ISSN 1740-7745

Seligmann, JF, Fisher, DJ, Brown, LC et al. (19 more authors) (2021) Inhibition of WEE1 Is Effective in TP53- and RAS-Mutant Metastatic Colorectal Cancer: A Randomized Trial (FOCUS4-C) Comparing Adavosertib (AZD1775) With Active Monitoring. Journal of Clinical Oncology, 39 (33). pp. 3705-3715. ISSN 0732-183X

Adams, RA, Fisher, DJ, Graham, J et al. (19 more authors) (2021) Capecitabine Versus Active Monitoring in Stable or Responding Metastatic Colorectal Cancer After 16 Weeks of First-Line Therapy: Results of the Randomized FOCUS4-N Trial. Journal of Clinical Oncology. JCO.21.01436-JCO.21.01436. ISSN 0732-183X

Yin, J, Cohen, R, Jin, Z et al. (23 more authors) (2021) Prognostic and Predictive Impact of Primary Tumor Sidedness for Previously Untreated Advanced Colorectal Cancer. Journal of the National Cancer Institute. ISSN 0027-8874

Malla, SB, Fisher, DJ, Domingo, E et al. (29 more authors) (2020) In-depth clinical and biological exploration of DNA Damage Immune Response (DDIR) as a biomarker for oxaliplatin use in colorectal cancer. Clinical Cancer Research. ISSN 1078-0432

Blagden, SP, Cook, AD, Poole, C et al. (16 more authors) (2020) Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trial. The Lancet Oncology, 21 (7). pp. 969-977. ISSN 1470-2045

Clamp, AR, James, EC, McNeish, IA et al. (26 more authors) (2019) Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial. The Lancet, 394 (10214). pp. 2084-2095. ISSN 0140-6736

Cross, W, Kovac, M, Mustonen, V et al. (53 more authors) (2018) The evolutionary landscape of colorectal tumorigenesis. Nature Ecology & Evolution, 2 (10). pp. 1661-1672. ISSN 2397-334X

Adams, R, Brown, E, Brown, L et al. (14 more authors) (2018) Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2–3 randomised trial. Lancet Gastroenterology and Hepatology, 3 (3). pp. 162-171. ISSN 2468-1253

Stark, D orcid.org/0000-0002-6172-733X, Cook, A, Brown, J orcid.org/0000-0002-2719-7064 et al. (8 more authors) (2017) Quality of life with cediranib in relapsed ovarian cancer: The ICON6 phase 3 randomized clinical trial. Cancer, 123 (14). pp. 2752-2761. ISSN 0008-543X

Downing, A orcid.org/0000-0002-0335-7801, Morris, EJA orcid.org/0000-0002-1075-6544, Corrigan, N et al. (13 more authors) (2017) High hospital research participation and improved colorectal cancer survival outcomes: a population-based study. Gut, 66 (1). pp. 89-96. ISSN 0017-5749

Zhou, C, Clamp, A, Backen, A et al. (9 more authors) (2016) Systematic Analysis of Circulating Soluble Angiogenesis-Associated Proteins in ICON7 Identifies Tie2 as a Biomarker of Vascular Progression on Bevacizumab. British Journal of Cancer, 115 (2). pp. 228-235. ISSN 0007-0920

Smith, CG, Fisher, D, Harris, R et al. (15 more authors) (2015) Analyses of 7,635 Patients with Colorectal Cancer Using Independent Training and Validation Cohorts Show That rs9929218 in CDH1 Is a Prognostic Marker of Survival. Clinical Cancer Research, 21 (15). pp. 3453-3461. ISSN 1078-0432

Oza, AM, Cook, AD, Pfisterer, J et al. (21 more authors) (2015) Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. Lancet Oncology, 16 (8). pp. 928-936. ISSN 1470-2045

Venderbosch, S, Nagtegaal, ID, Maughan, TS et al. (13 more authors) (2014) Mismatch Repair Status and BRAF Mutation Status in Metastatic Colorectal Cancer Patients: A Pooled Analysis of the CAIRO, CAIRO2, COIN, and FOCUS Studies. Clinical Cancer Research, 20 (20). pp. 5322-5330. ISSN 1078-0432

Maughan, TS, Meade, AM, Adams, RA et al. (22 more authors) (2014) A feasibility study testing four hypotheses with phase II outcomes in advanced colorectal cancer (MRC FOCUS3): a model for randomised controlled trials in the era of personalised medicine? British Journal of Cancer, 110 (9). 2178 - 2186. ISSN 0007-0920

Smith, CG, West, H, Harris, R et al. (12 more authors) (2013) Role of the oxidative DNA damage repair gene OGG1 in colorectal tumorigenesis. Journal of the National Cancer Institute, 105 (16). 1249 - 1253. ISSN 0027-8874

Madi, A, Fisher, D, Wilson, RH et al. (9 more authors) (2012) Oxaliplatin/capecitabine vs oxaliplatin/infusional 5-FU in advanced colorectal cancer: the MRC COIN trial. British Journal of Cancer, 107 (7). pp. 1037-1043. ISSN 0007-0920

Proceedings Paper

Richman, SD orcid.org/0000-0003-3993-5041, Adams, R, Brown, E et al. (14 more authors) (2017) FOCUS4: MAMS Trial Design in Action. Early Closure of FOCUS4-D (Pan-HER 1, 2 and 3 Inhibitor Versus Placebo) in Advanced Colorectal Cancer (aCRC) Patients, with Tumours Wildtype (WT) for KRAS, NRAS, bRAF and PIK3CA. In: Journal of Pathology. Belfast Pathology 2017: 10th Joint Meeting of the British Division of the International Academy of Pathology and the Pathological Society of Great Britain & Ireland, 20-23 Jun 2017, Belfast, Northern Ireland, UK. Wiley , S13-S13.

Adams, RA, Brown, E, Brown, L et al. (13 more authors) (2016) FOCUS4-D: Results from a randomised, placebo controlled trial (RCT) of AZD8931 (an inhibitor of signalling by HER1, 2, and 3) in patients (pts) with advanced or metastatic colorectal cancer (aCRC) in tumours that are wildtype (wt) for BRAF, PIK3CA, KRAS & NRAS. In: Annals of Oncology. 41st ESMO Congress (ESMO 2016), 07-11 Oct 2016, Copenhagen. Oxford University Publishing .